Search This Blog

Tuesday, February 11, 2025

Regeneron Linvoseltamab BLA Accepted for Relapsed/Refractory Multiple Myeloma

 Acceptance follows resolution of third-party fill/finish manufacturing issues

FDA decision expected by July 10, 2025

https://www.globenewswire.com/news-release/2025/02/11/3024043/0/en/Linvoseltamab-BLA-Accepted-for-FDA-Review-for-the-Treatment-of-Relapsed-Refractory-Multiple-Myeloma.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.